Health-Related Quality of Life for individuals with hepatitis C: A narrative review

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 936-949

  Whiteley, David ^a,b,d   Elliott, Lawrie ^b   Cunningham Burley, Sarah ^c   Whittaker, Anne ^b,d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ASTLEY AINSLIE HOSPITAL   (United Kingdom)

Author keywords

Health Related Quality of Life; Hepatitis C; Injecting drug users; Lived experience

Indexed keywords

INTERFERON;

ATTITUDE TO ILLNESS; CAUSAL ATTRIBUTION; COMORBIDITY; FATIGUE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; INTROSPECTION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STIGMA; SUBSTANCE USE; SYMPTOM; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; COST OF ILLNESS; PSYCHOLOGY; SOCIAL STIGMA;

COST OF ILLNESS; HEPATITIS C; HUMANS; QUALITY OF LIFE; SOCIAL STIGMA;

EID: 84941803514     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.04.019     Document Type: Short Survey

References (147)

1. AASLD, IDSA Recommendations for testing, managing and treating hepatitis C 2014, Available from, Accessed 29.09.14. http://www.hcvguidelines.org/fullreport.
2. Arora S., O'Brien C., Zeuzem S., Shiffman M., Diago M., Tran A., et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α-2a (40kDa) plus ribavirin: Impact on health-related quality of life. Journal of Gastroenterology and Hepatology 2006, 21(2):406-412.
3. Australasian Hepatology Association AHA consensus-based nursing guidelines for the care of patients with hepatitis B, hepatitis C, advanced liver disease and hepatocellular carcinoma 2012, Available from, Accessed 02.10.14. http://www.hepatologyassociation.com.au/external/downloads/AHA_Guidelines_WEB.pdf.
4. Balfour L., Cooper C., Kowal J., Tasca G., Silverman A., Kane M., et al. Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C. Canadian Journal of Gastroenterology 2006, 20(2):81-86.
5. Batki S., Canfield K., Smyth E., Ploutz-Snyder R. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug and Alcohol Dependence 2009, 101(3):176-182.
6. Bayliss M., Gandek B., Bungay K., Sugano D., Hsu M., Ware J. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research 1998, 7(1):39-55.
7. Beinhardt S., Staettermayer A., Rutter K., Maresch J., Scherzer T., Steindl-Munda P., et al. Treatment of chronic hepatitis C genotype 1 patients at an academic centre in Europe involved in prospective, controlled trials: Is there a selection bias?. Hepatology 2012, 55(1):30-38.
8. Bernstein D., Kleinman L., Barker C., Revicki D., Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35(3):704-708.
9. Bezemer G., Van Gool A., Verheij-Hart E., Hansen B., Lurie Y., Esteban J., et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicentre, randomized, controlled study. BMC Gastroenterology 2012, 12:11. the DITTO-HCV Study Group. 10.1186/1471-230X-12-11.
10. Bianchi G., Loguercio C., Sgarbi D., Abbiati R., Chen C., Di Pierro M., et al. Reduced quality of life in patients with chronic hepatitis C: Effects of interferon treatment. Digestive and Liver Disease 2000, 32(5):398-405.
11. Bini E., Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Alimentary Pharmacology and Therapeutics 2006, 23(6):777-785.
12. Björnsson E., Verbaan H., Oksanen A., Frydén A., Johansson J., Friberg S., et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology 2009, 44(7):878-887.
13. Bondini S., Kallman J., Dan A., Younoszai Z., Ramsey L., Nader F., et al. Health-related quality of life in patients with chronic hepatitis B. Liver International 2007, 27(8):1119-1125.
14. Bonkovsky H., Snow K., Malet P., Back-Madruga C., Fontana R., Sterling R., et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of Hepatology 2007, 46(3):420-431. the Halt-C Trial Group.
15. Bonkovsky H., Woolley J. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999, 29(1):264-270. the Consensus Interferon Study Group.
16. Britton A., McKee M., McPherson K., Sanderson C., Bain C. Threats to applicability of randomised trials: Exclusions and selective participation. Journal of Health Services Research & Policy 1999, 4(2):112-121.
17. Bury M. Chronic illness as biographical disruption. Sociology of Health and Illness 1982, 4(2):167-182.
18. Butt G., Paterson B., McGuinness L. Living with the stigma of hepatitis C. Western Journal of Nursing Research 2008, 30(2):204-221.
19. Carricaburu D., Pierret J. From biographical disruption to biographical reinforcement: The case of HIV-positive men. Sociology of Health and Illness 1995, 17(1):65-88.
20. Carrier N., LaPlante J., Bruneau J. Exploring the contingent reality of biomedicine: Injecting drug users, hepatitis C virus and risk. Health, Risk & Society 2005, 7(2):123-140.
21. Chang S., Yang S., Chang C., Lin C., Chung Y., Li T. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health and Quality of Life Outcomes 2014, 12:97. 10.1186/1477-7525-12-97.
22. Chapman F., McManus A. Hepatitis C treatment - better outcomes through partner support. Australasian Medical Journal 2012, 5(11):585-588.
23. Chen J., Florian J., Carter W., Fleischer R., Hammerstrom T., Jadhav P., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis therapies. Gastroenterology 2013, 144(7):1450-1455.
24. Choo Q., Kuo G., Weiner A., Overby L., Bradley D., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
25. Conrad S., Garrett L., Cooksley W., Dunne M., MacDonald G. Living with chronic hepatitis C means 'you just haven't got a normal life anymore'. Chronic Illness 2006, 2(2):121-131.
26. Conteduca V., Sansonno D., Russi S., Pavone F., Dammacco F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. Journal of Infection 2014, 68(1):1-20.
27. Copeland L. The drug users' identity and how it relates to being hepatitis C antibody positive: A qualitative study. Drugs, Education, Prevention and Policy 2004, 11(2):129-147.
28. Córdoba J., Flavià M., Jacas C., Sauleda S., Esteban J., Vargas V., et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology 2003, 39(2):231-238.
29. Cullen W., Kelly Y., Stanley J., Langton D., Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Irish Medical Journal 2005, 98(3):73-74.
30. Dalgard O., Egeland A., Skaug K., Vilimas K., Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004, 39(1):74-80.
31. Dan A., Martin L., Crone C., Ong J., Farmer D., Wise T., et al. Depression, anemia and health-related quality of life in chronic hepatitis C. Journal of Hepatology 2006, 44(3):491-498.
32. Danoff A., Khan O., Wan D., Hurst L., Cohen D., Tenner C., et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. American Journal of Gastroenterology 2006, 101(6):1235-1243.
33. Davis M., Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. International Journal of Drug Policy 2004, 15:123-131.
34. Desmorat H., Combis J., Pradat P. Assessment of quality of life in chronic hepatitis C: Effect of treatment. Gastroentérologie Clinique et Biologique 2003, 27(12):1084-1090.
35. El Khoury A., Vietri J., Prajapati G. The burden of untreated hepatitis C virus infection: A US patients' perspective. Digestive Diseases and Sciences 2012, 57(11):2995-3003.
36. European Association for the Study of the Liver EASL clinical practice guidelines: Management of hepatitis C virus infection. Hepatology 2014, 60:392-420.
37. Faye B., Irurita V. Balancing perspective: The response to feelings of being condemned with the hepatitis C virus. Journal of Substance Use 2003, 8(2):92-103.
38. Fayers P., Machin D. Quality of life: The assessment, analysis and interpretation of patient-reported outcomes 2007, John Wiley & Sons Ltd, Chichester. 2nd ed.
39. Fischer J., Conrad S., Clavarino A., Kemp R., Najman J. Quality of life of people who inject drugs: Characteristics and comparisons with other population samples. Quality of Life Research 2013, 22:2113-2121.
40. Fleming C., Christiansen D., Nunes D., Heeren T., Thornton D., Horsburgh C., et al. Health-related quality of life of patients with HIV disease: Impact of hepatitis C coinfection. Clinical Infectious Diseases 2004, 38(4):572-578.
41. Food & Drug Administration Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims 2009, Available from, Accessed 03.09.14. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
42. Fontana R., Moyer C., Sonnad S., Lok A., Sneed-Pee N., Walsh J., et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C American. Journal of Gastroenterology 2001, 96(1):170-178.
43. Forton D., Karayiannis P., Mahmud N., Taylor-Robinson S., Thomas H. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. Journal of Virology 2004, 78(10):5170-5183.
44. Foster G. Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis 2009, 16:605-611.
45. Foster G., Goldin R., Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998, 27(1):209-212.
46. Fraenkel L., McGraw S., Wongcharatrawee S., Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C?. American Journal of Medicine 2005, 118:1387-1391.
47. Fraenkel L., McGraw S., Wongcharatrawee S., Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient Education and Counseling [sic] 2006, 62:148-155.
48. Fraser S., Treloar C. 'Spoiled Identity' in hepatitis C infection: The binary logic of despair. Critical Public Health 2006, 16(2):99-110.
49. Fry M., Bates G. The tasks of self-managing hepatitis C: The significance of disclosure. Psychology and Health 2012, 27(4):460-474.
50. Gao X., Stephens J., Carter J., Haider S., Rustgi V. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 2012, 12(3):335-343.
51. Gallegos-Orozco J., Fuentes A., Gerardo Argueta J., Pérez-Pruna C., Hinojosa-Becerril C., Sixtos-Alonso M., et al. Health-related quality of life and depression in patients with chronic hepatitis C. Archives of Medical Research 2003, 34(2):124-129.
52. Gillis J., Cooper C., Rourke S., Ruedo S., O'Brien K., Collins E., et al. Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Quality of Life Research 2013, 22:1525-1535.
53. Gjeruldsen S., Loge J., Opjordsmoen S. Drug addiction in hepatitis C patients leads to a lower quality of life. Nordic Journal of Psychiatry 2006, 60(2):157-161.
54. Glacken M., Coates V., Kernohan G., Hegarty J. The experience of fatigue for people living with hepatitis C. Journal of Clinical Nursing 2003, 12:244-252.
55. Glacken M., Kernohan G., Coates V. Diagnosed with Hepatitis C: A descriptive exploratory study. International Journal of Nursing Studies 2001, 38:107-116.
56. Groessl E., Weingart K., Kaplan R., Clark J., Gifford A., Ho S. Living with hepatitis C: Qualitative interviews with hepatitis C-infected veterans. Journal of General Internal Medicine 2008, 23(12):1959-1965.
57. Grundy G., Beeching N. Understanding social stigma in women with hepatitis C. Nursing Standard 2004, 19(4):35-39.
58. Harris M. Troubling biographical disruption: Narratives of unconcern about hepatitis C diagnosis. Sociology of Health and Illness 2009, 31(7):1028-1042.
59. Hassanein T., Cooksley G., Sulkowski M., Smith C., Marinos G., Lai M., et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology 2004, 40:675-681.
60. Häuser W., Zimmer C., Schiedermaier P., Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosomatic Medicine 2004, 66:954-958.
61. Helbling B., Overbeck K., Gonvers J.-J., Malinverni R., Dufour J.-F., Borovicka J., et al. Host-rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008, 57:1597-1603.
62. Hill R., Pfeil M., Moore J., Richardson B. Living with hepatitis C: A phenomenological study. Journal of Clinical Nursing 2014, (May). 10.1111/jocn.12620.
63. Hollander A., Foster G., Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology 2006, 41:577-585.
64. Hopwood M., Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qualitative Health Research 2005, 15(5):635-646.
65. Hopwood M., Treloar C. Resilient coping: Applying adaptive responses to prior adversity during treatment for hepatitis C. Journal of Health Psychology 2008, 13(1):17-27.
66. Hsu P., Federico C., Krajden M., Yoshida E., Bremner K., Weiss A., et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology 2012, 27(1):149-157.
67. Hsu P., Krajden M., Yoshida E., Anderson F., Tomlinson G., Krahn M. Does cirrhosis affect quality of life in hepatitis C virus-infected patients?. Liver International 2009, 29(3):449-458.
68. Hunt C., Dominitz J., Philips Bute B., Waters B., Blasi U., Williams D. Effect of interferon-α treatment on chronic hepatitis C on health-related quality of life. Digestive Diseases and Sciences 1997, 42(12):2482-2486.
69. Hussain K., Fontana R., Moyer C., Su G., Sneed-Pee N., Lok A. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology 2001, 96(9):2737-2744.
70. Hutchinson S., Roy K., Wadd S., Bird S., Taylor A., Anderson E., et al. Hepatitis C virus infection in Scotland: Epidemiological review and public health challenges. Scottish Medical Journal 2006, 51:8-15.
71. Isaacs D., Abdelaziz N., Keller M., Tibble J., Haq I. Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepatitis Research and Treatment 2013, 2013:910519. 10.1155/2013/910519.
72. Jahagirdar D., Kroll T., Ritchie K., Wyke S. Patient-reported outcome measures for chronic obstructive pulmonary disease: The exclusion of people with low literacy skills and learning disabilities. Patient 2013, 6(1):11-21.
73. Janke E., McGraw S., Garcia-Tsao G., Fraenkel L. Psychosocial issues in hepatitis C: A qualitative analysis. Psychosomatics 2008, 49(6):494-501.
74. Jerkeman A., Norkrans G., Lidman C., Westin J., Lagging M., Frimand J., et al. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy. European Journal of Gastroenterology and Hepatology 2014, 26(5):523-531.
75. Jiwani N., Begum Gal R., Ali A., Salih M., Hanzala M. Experiences and perceptions of patients living with hepatitis C in Karachi, Pakistan. Journal of Transcultural Nursing 2013, 24(3):297-304.
76. John-Baptiste A., Tomlinson G., Hsu P., Krajden M., Heathcote J., Laporte A., et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. American Journal of Gastroenterology 2009, 104:2439-2448.
77. Jones K. Mission drift in qualitative research, or moving toward a systematic review of qualitative studies, moving back to a more systematic narrative review. Qualitative Report 2004, 9(1):95-112.
78. Kallman J., O'Neil M., Larive B., Boparai N., Calabrese L., Younossi Z. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Digestive Diseases and Sciences 2007, 52:2531-2539.
79. Kang S., Hwang S., Lee S., Chang F., Lee S. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World Journal of Gastroenterology 2005, 11(47):7494-7498.
80. Karaivazoglou K., Iconomou G., Triantos C., Hyphantis T., Thomopoulos K., Lagadinou M., et al. Fatigue and depressive symptoms associated with chronic viral hepatitis patients health-related quality of life (HRQOL). Annals of Hepatology 2010, 9(4):419-427.
81. Kemmer N., Hua L., Anderson J., Chung R., Butt A., Sherman K., et al. Health-related quality of life in subjects with HCV/HIV coinfection: Results from ACTG 5178 study. Journal of Viral Hepatitis 2012, 19:792-800.
82. Kramer L., Bauer E., Funk G., Hofer H., Jessner W., Steindl-Munda P., et al. Subclinical impairment of brain function in chronic hepatitis C infection. Journal of Hepatology 2002, 37(3):349-354.
83. Kramer L., Hofer H., Bauer E., Funk G., Formann E., Steindl-Munda P., et al. Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS 2005, 19(Suppl. 3):S85-S92.
84. Kuwashiro T., Mizuta T., Kawaguchi Y., Iwane S., Takahashi H., Oza N., et al. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance. Journal of Gastroenterology 2014, 49(2):317-323.
85. Kwan J., Cronkite R., Yiu A., Goldstein M., Kazis L., Cheung R. The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Quality of Life Research 2008, 17:715-724.
86. Lekas H., Siegel K., Leider J. Felt and enacted stigma among HIV/HCV-coinfected adults: The impact of stigma layering. Qualitative Health Research 2011, 21(9):1205-1219.
87. Lenton E., Fraser S., Moore D., Treloar C. Hepatitis C, love and intimacy: Beyond the 'anomalous body'. Drugs: Education, Prevention and Policy 2011, 18(3):228-236.
88. Lim J., Cronkite R., Goldstein M., Cheung R. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. Journal of Clinical Gastroenterology 2006, 40(6):528-534.
89. Liu G., Dibonaventura M., Yuan Y., Wagner J., L'Italien G., Langley P., et al. The burden of illness for patients with viral hepatitis C: Evidence from a national survey in Japan. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 2012, 15(1 Suppl.):S65-S71.
90. McDonald S., Hutchinson S., Palmateer N., Allen E., Cameron S., Goldberg D., et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. Journal of Hepatology 2013, 58:460-466.
91. McHutchison J., Ware J., Bayliss M., Pianko S., Albrecht J., Cort S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Journal of Hepatology 2001, 34:140-147.
92. Mandorfer M., Payer B., Scheiner B., Breitenecker F., Aichelburg M., Grabmeier-Pfistershammer K., et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver International 2014, 34(1):69-77.
93. Manos M., Ho C., Murphy R., Shvachko V. Physical, social, and psychological consequences of treatment for hepatitis C: A community-based evaluation of patient-reported outcomes. Patient 2013, 6(1):23-34.
94. Marcellin P., Chousterman M., Fontanges T., Ouzan D., Rotily M., Varastet M., et al. Adherence to treatment and quality of life during hepatitis C therapy: A prospective, real-life, observational study. Liver International 2011, 31(4):516-524.
95. Martin C., Peterson C. The social construction of chronicity - A key to understanding chronic care transformations. Journal of Evaluation in Clinical Practice 2009, 15:578-585.
96. Mathew A., Peiffer L., Rhoades K., McGarrity T. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with pegylated interferon alpha-2b and ribavirin. Health and Quality of Life Outcomes 2006, 4(30). 10.1186/1477-7525-4-30.
97. Matsushita H., Ikeda F., Iwasaki Y., Seki H., Nanba S., Takeuchi Y., et al. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology and Hepatology 2014, 29:337-343.
98. Miller E., Hiller J., Shaw D. Quality of life in HCV-infection: Lack of association with ALT levels. Australian and New Zealand Journal of Public Health 2001, 25(4):355-361.
99. Miller E., McNally S., Wallace J., Schlichthorst M. The ongoing impacts of hepatitis C - A systematic narrative review of the literature. BMC Public Health 2012, 12:672.
100. Munoz-Plaza C. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. International Journal of Drug Policy 2008, 19(1):71-78.
101. Olsen A., Banwell C., Dance P. Reinforced biographies among women living with hepatitis C. Qualitative Health Research 2012, 23(4):531-540.
102. Palmateer N., Hutchinson S., Innes H., Schnier C., Wu O., Goldberg D., et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence among people who inject drugs in Europe. International Journal of Drug Policy 2013, 24:85-100.
103. Paterson B., Backmund M., Hirsch G., Yim C. The depiction of stigmatization in research about hepatitis C. International Journal on Drug Policy 2007, 18:364-373.
104. Paterson B., Butt G., McGuinness L., Moffat B. The construction of hepatitis C as a chronic illness. Clinical Nursing Research 2006, 15(3):209-224.
105. Perrillo R., Rothstein K., Rubin R., Alam I., Imperial J., Harb G. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as intitial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis 2004, 11(2):157-165.
106. Pojoga C., Dumitraşcu D., Pascu O., Grigorescu M. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience. Journal of Gastrointestinal and Liver Diseases 2006, 15(1):31-35.
107. Public Health England Hepatitis C in the UK: 2014 report 2014, Available from, Accessed 03.09.14. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/337115/HCV_in_the_UK_2014_24_July.pdf.
108. Quarantini L., Miranda-Scippa A., Batista-Neves S., Galvão-de-Almeida A., Lacerda A., Moriyama T., et al. The effect of early virological response in health-related quality of life in HCV-infected patients. Journal of Medical Virology 2008, 80:419-423.
109. ®-A] in patients with chronic hepatitis C. Pharmacoeconomics 2003, 21(5):341-349.
110. Rasi M., Künzler-Heule P., Schmid P., Semela D., Bruggmann P., Fehr J., et al. "Fighting an uphill battle": Experience with the HCV triple therapy: A qualitative thematic analysis. BMC Infectious Diseases 2014, 14:507. http://www.biomedcentral.com/1471-2334/14/507.
111. Refolo P., Minacori R., Mele V., Sacchini D., Spagnolo A. Patient-reported outcomes (PROs): The significant of using humanistic measures in clinical trial and clinical practice. European Review for Medical and Pharmacological Sciences 2012, 16:1319-1323.
112. Rodger A., Jolley D., Thompson S., Lanigan A., Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999, 30(5):1299-1301.
113. Rowan P., Al-Jurdi R., Tavakoli-Tabasi S., Kunik M., Satrom S., El-Serag H. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. Journal of Clinical Gastroenterology 2005, 39(8):731-736.
114. Roy É., Nonn É., Haley N., Cox J. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montréal. International Journal of Drug Policy 2007, 18:397-405.
115. Schwarzinger M., Dewedar S., Rekacewicz C., Abd Elaziz K., Fontanet A., Carrat F., et al. Chronic hepatitis c infection: Does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004, 40(6):1434-1441.
116. Scottish Government The healthcare quality strategy for NHS Scotland 2010, Available from, Accessed 03.09.14. http://www.scotland.gov.uk/Resource/Doc/311667/0098354.pdf.
117. Scottish Intercollegiate Guidelines Network SIGN 133: Management of hepatitis C: A national clinical guideline July 2013 2013, Available from, Accessed 29.09.14. http://www.sign.ac.uk/pdf/sign133.pdf.
118. Seeff L. The natural history of chronic hepatitis C. Hepatology 2002, 36(5 Suppl. 1):S35-S46.
119. Sgorbini M., O'Brien L., Jackson D. Living with hepatitis C and treatment: The personal experiences of patients. Journal of Clinical Nursing 2009, 18:2282-2291.
120. Sheppard K., Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterology Nursing 2006, 29(4):309-315.
121. Sinakos E., Gigi E., Lalla T., Bellou A.-L., Sykja A., Orphanou E., et al. Health-related quality of life in greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. Hippokratia 2010, 14(2):122-125.
122. Snow K., Bonkovsky H., Fontana R., Kim H.-Y., Sterling R., Di Bisceglie A., et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2010, 31:719-734. the Halt-C Trial Group.
123. Strauss E., Porto-Ferreira F., Almeida-Neto C., Teixeira M. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clinics and Research in Hepatology and Gastroenterology 2014, 38:40-45.
124. Sutton R., Treloar C. Chronic illness experiences, clinical markers and living with hepatitis C. Journal of Health Psychology 2007, 12(2):330-340.
125. Swan D., Long J., Carr O., Flanagan J., Irish H., Keating S., et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs 2010, 24(12):753-762.
126. Taliani G., Rucci P., Biliotti E., Cirrincione L., Aghemo A., Alberti A., et al. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. Journal of Viral Hepatitis 2007, 14:875-882.
127. Taylor-Young P., Hildebrandt E. The multidimensional burden of hepatitis C and its treatment. Gastroenterology Nursing 2009, 32(3):180-187.
128. Teixeira M., Ribeiro Mde F., Gayotto L., ChamoneDde A., Strauss E. Worse quality of life in volunteer blood donors with hepatitis C. Transfusion 2006, 46(2):278-283.
129. Temple-Smith M., Gifford S., Stoové M. The lived experience of men and women with hepatitis C: Implications for support needs and health information. Australian Health Review 2004, 27(2):46-56.
130. Thein H., Butler T., Krahn M., Rawlinson W., Levy M., Kaldor J., et al. The effect of hepatitis C virus infection on health-related quality of life in prisoners. Journal of Urban Health: Bulletin of the New York Academy of Medicine 2006, 83(2):275-288.
131. Thein H., Maruff P., Krahn M., Kaldor J., Koorey D., Brew B., et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Medicine 2007, 8:520-528.
132. Tillmann H., Wiese M., Braun Y., Wiegand J., Tenckhoff S., Mössner J., et al. Quality of life in patients with various liver diseases: Patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. Journal of Viral Hepatitis 2011, 18:252-261.
133. Tompkins C., Wright N., Jones L. Impact of a positive hepatitis c diagnosis on homeless injecting drug users: A qualitative study. British Journal of General Practice 2005, 55:263-268.
134. Treloar C., Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: Qualitative synthesis. Qualitative Health Research 2009, 19(9):1321-1334.
135. Van Spall H., Toren A., Kiss K., Fowler R. Eligibility criteria of randomised controlled trials published in high-impact general medical journals: A systematic sampling review. Journal of the American Medical Association 2007, 297(11):1233-1240.
136. Vera-Llonch M., Martin M., Aggarwal J., Donepudi M., Bayliss M., Goss T., et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary Pharmacology and Therapeutics 2013, 38:124-133.
137. von Wagner M., Lee J.-H., Kronenberger B., Friedl R., Sarrazin C., Teuber G., et al. Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. Journal of Viral Hepatitis 2006, 13:828-834.
138. Ware J., Bayliss M., Mannocchia M., Davis G., the International Hepatitis Interventional Therapy Group Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999, 30(2):550-555.
139. Ware J., Sherbourne C. The MOS 36-item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992, 30(6):473-483.
140. Williams S. Chronic illness as biographical disruption or biographical disruption as chronic illness?. Sociology of Health and Illness 2000, 22(1):40-67.
141. World Health Organisation Hepatitis C: Fact sheet no. 164 updated April 2014 2014, Available from, Accessed 07.05.14. http://www.who.int/mediacentre/factsheets/fs164/en/.
142. Wozniak L., Prakash M., Taylor M., Wild T. Everybody's got it, but. . .: Situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada. International Journal of Drug Policy 2007, 18:388-396.
143. Wu A., Snyder C. Getting ready for patient-reported outcomes measures (PROMs) in clinical practice. Healthcare Papers 2012, 11(4):48-53.
144. Younossi Z., Stepanova M., Henry L., Gane E., Jacobson I., Lawitz E., et al. Minimal impact of sofosbuvir and ribavirin on health-related quality of life in chronic hepatitis C (CH-C). Journal of Hepatology 2014, 60(4):741-747.
145. Younossi Z., Stepanova M., Nader F., Jacobson I., Gane E., Nelson D., et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014, 59(6):2161-2169.
146. Younossi Z., Stepanova M., Zeuzem S., Dusheiko G., Esteban R., Hezode C., et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. Journal of Hepatology 2014, 61(2):228-234.
147. Zickmund S., Ho E., Masuda M., Ippolito L., Labrecque D. "They treated me like a leper" stigmatization and the quality of life of patients with hepatitis C. Journal of General Internal Medicine 2003, 18:835-844.